blood count News
-
PixCell Medical Partners with Triolab to Distribute Hematological Analyzer HemoScreen in Sweden
PixCell Medical, innovator of rapid diagnostic solutions at the point-ofcare, today announced a partnership with Triolab, the largest diagnostics distributor in the Nordic and Baltic countries, to be the sole distributor in Sweden of the HemoScreen™, PixCell’s hematology analyzer designed for use at the point of care. “PixCell’s HemoScreen brings lab-quality haematology ...
-
RURAL Cohort Study to Utilize PixCell Medical`s HemoScreen Hematology Analyzer for Research Initiative
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that the Risk Underlying Rural Areas Longitudinal Study (RURAL) has selected PixCell's novel miniaturized, portable hematology analyzer, HemoScreen™, as part of its six year research study, aiming to gain insight into the specific health-related concerns of the rural southeastern United States' ...
-
Sight Diagnostics raises $71 million amidst Covid-19 demand for blood count devices
Israeli blood testing startup S.D. Sight Diagnostics Ltd. has raised $71 million from international venture capital funds and U.S. corporations, Clal Biotechnology Industries Ltd. revealed in a report sent to the Tel Aviv Stock Exchange last week. Sight Diagnostics has yet to announce the details of the new funding round, but Clal Biotechnology Industries stated in its report that following the ...
-
PixCell Medical Opens United States Subsidiary to Support Commercial Growth
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced the opening of a United States subsidiary in the Denver metropolitan area. The new office will increase logistical and commercial support for PixCell's U.S. clients and will handle order fulfilment across the country, as well as provide additional clinical and technical support to customers. "Opening a ...
-
PixCell Medical`s Point-Of-Care Hematology Analyzer Can Play a Key Role in Minimizing Disease Spread
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that The Journal of Applied Laboratory Medicine (JALM) has published a research paper comparing PixCell's HemoScreen™ and its analysis method to standard lab analyzers. Researchers concluded that PixCell's HemoScreen™, a miniature, easy-to-use, AI and machine vision-enabled hematology ...
-
Sysmex Continues to Evolve Its Hematology Product Portfolio
Since its founding in 1968, Sysmex has developed its business by focusing on the hematology field (blood cell count tests), which analyzes the number, type, and size of red and white blood cells as well as platelets. Sysmex has adopted a modular concept since the launch of the XN-Series Automated Hematology Analyzer (“XN-Series”) in 2011, combining modules for blood count, smear ...
-
Aidian Appointed Sole Distributor of PixCell Medical’s Point-of-Care Hematological Analyzer HemoScreen in the Nordics
PixCell Medical, innovator of rapid diagnostic solutions at the point-ofcare, today announced a partnership with Aidian, a Finland-based in-vitro diagnostics company providing reliable, fast, and easy-to-use diagnostic tests for primary care. Aidian will serve as the sole distributor of PixCell’s HemoScreen™, a hematology analyzer designed for use at the point of care, with exclusive ...
-
PixCell Medical Announces Acquisition by Soulbrain Holdings
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that Soulbrain Holdings has acquired all controlling PixCell shares, as well as investing in the company, making Soulbrain the majority shareholder of PixCell Medical. The acquisition of PixCell aligns with Soulbrain's recent strategic transition into the healthcare and in-vitro diagnostics space. ...
-
PixCell Medical Announces Regulatory Approval from Australian Therapeutic Goods Administration (TGA) for HemoScreen Point-of-Care Hematology Analyzer
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that it has received regulatory approval from the Australian Therapeutic Goods Administration (TGA) for the HemoScreen™, PixCell's hematology analyzer that offers a 5-part differential CBC intended for point-of-care (POC) use. Under the TGA approval, PixCell's HemoScreen is cleared for use with ...
-
PixCell Medical and Gamidor Diagnostics Partner to Introduce Point-of-Care Hematology Analysis in Israelq
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced it has signed an exclusive distribution agreement with medical diagnostics company Gamidor Diagnostics to distribute the HemoScreen™, PixCell's hematology analyzer, across Israel. This deal follows a global shift spurred by the COVID-19 pandemic towards near-patient, digitally connected testing ...
-
PixCell Medical Partners with Axonlab to Distribute Point-of-Care Hematological Analyzer HemoScreen Across Europe
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced an exclusive distribution agreement with Axonlab, a leader in point-of-care testing in Europe providing the healthcare sector with equipment and services in the fields of medical diagnostics, life science, and software solutions, to distribute the HemoScreen™, PixCell's hematology analyzer, in key ...
-
HORIBA Medical welcomes the latest member of the new Yumizen H500 family
As a result of a growing research and development program, HORIBA Medical has recently developed two new products that aim to better meet the needs of today's clinical laboratories : The Yumizen H500 OT ‘Open Tube’ with flexible sampling to accommodate all sample types, particularly for rapid screening in critical care, emergency care and pediatric clinics. The new released ...
-
PixCell Medical Signs Point of Care Diagnostics as Sole Distributor of HemoScreen™ in Australasia Region
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that it has signed a distribution agreement with Point of Care Diagnostics Aus. Pty Ltd (POCD), supplier and distributor of point-of-care testing solutions to Australasia, making POCD the sole regional distributor of the HemoScreen™, a small-sized, simple-to-operate diagnostic platform designed ...
-
A Complete Overview of a Life Saving Treatment - Liver Transplantation in India
Hepatic transplant or liver transplant is a treatment that includes the replacement of diseased liver with the healthy liver from another individual. It is a surgical treatment to remove the non-functional liver (liver failure) and replace it with the healthy liver (from a deceased donor) or a part of the healthy liver (from a living donor). Few important matters regarding liver transplantation ...
-
Groundbreaking new methodology published in Nature Medicine uncovers the missing numbers to the only clock that really matters in the body – your immune age
There is the age you say you are – which is not always accurate but always medically irrelevant. There is your chronological age – which is accurate but ignores inter-person variation. And then there is your immune age – the key determinant of future health and response to disease and treatment – quantified now for the first time, creating a potential paradigm shift ...
By CytoReason
-
Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)
Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome ...
-
Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer
Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be ...
-
Preventing Wound Infections and Complications at Urgent Care
Cuts and lacerations are among the most common complaints that bring patients to urgent care clinics. Whether a wound originates from an accident with a sharp object, such as a kitchen knife or yard tool, or from a blunt force such as a fall, there may be a risk of infection. Urgent care providers are responsible for providing treatment that promotes healing and helps prevent wound infection. ...
-
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen
Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...
-
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you